Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2020-12-15 Regulatory Filings
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from the CEO of Sonoma Pharmaceuticals, Inc. responding to comments from the SEC staff regarding a Registration Statement on Form S-3 filed on November 24, 2020. The letter addresses specific SEC comments and the company's responses, indicating it is part of the regulatory review process for a securities registration filing. The document is short (2315 characters) and is a correspondence related to a regulatory filing rather than the filing itself. It does not contain financial statements or detailed financial data, nor is it a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with regulatory bodies that do not fit other categories.
2020-12-15 English
FORM S-3 AMENDMENT 1
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Amendment 1 registration statement filed with the SEC by Sonoma Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale, including common stock, preferred stock, debt securities, warrants, and units. The document includes details about the registration fee, offering price, and general terms of the securities to be offered. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration information, not just an announcement or a brief notice, so it is not an RPA or RNS. Confidence is high given the clear identification as a Form S-3 registration statement amendment.
2020-12-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 4, 2020, by Sonoma Pharmaceuticals, Inc. It reports the entry into a material definitive agreement, specifically an exclusive licensing and distribution agreement. The content focuses on announcing this new agreement rather than providing financial results, management discussion, or other report types. The document is not an annual or quarterly report, audit report, earnings release, or any other detailed financial or governance report. It is a current report disclosing a significant event (material definitive agreement) as required by SEC regulations. Therefore, the filing type corresponds to a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2020-12-10 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but without meaningful content, it cannot be classified as a financial or corporate report type.
2020-12-07 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering. It includes details about the types of securities to be offered (common stock, preferred stock, debt securities, warrants, units), the aggregate offering price, and the terms of the offering. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2020-11-24 English
FORM 10-Q
Interim / Quarterly Report Q2 2021
2020-11-20 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.